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B I O C H E M I S T R Y
Short linear motif candidates in the cell entry  
system used by SARS-CoV-2 and their potential 
therapeutic implications
Bálint Mészáros1*, Hugo Sámano-Sánchez1, Jesús Alvarado-Valverde1,2, Jelena Čalyševa1,2, 
Elizabeth Martínez-Pérez1,3, Renato Alves1, Denis C. Shields4, Manjeet Kumar1*, 
Friedrich Rippmann5, Lucía B. Chemes6*, Toby J. Gibson1*
The first reported receptor for SARS-CoV-2 on host cells was the angiotensin-converting enzyme 2 (ACE2). Howev-
er, the viral spike protein also has an RGD motif, suggesting that cell surface integrins may be co-receptors. We 
examined the sequences of ACE2 and integrins with the Eukaryotic Linear Motif (ELM) resource and identified 
candidate short linear motifs (SLiMs) in their short, unstructured, cytosolic tails with potential roles in endocyto-
sis, membrane dynamics, autophagy, cytoskeleton, and cell signaling. These SLiM candidates are highly con-
served in vertebrates and may interact with the 2 subunit of the endocytosis-associated AP2 adaptor complex, 
as well as with various protein domains (namely, I-BAR, LC3, PDZ, PTB, and SH2) found in human signaling and 
regulatory proteins. Several motifs overlap in the tail sequences, suggesting that they may act as molecular 
switches, such as in response to tyrosine phosphorylation status. Candidate LC3-interacting region (LIR) motifs 
are present in the tails of integrin 3 and ACE2, suggesting that these proteins could directly recruit autophagy 
components. Our findings identify several molecular links and testable hypotheses that could uncover mecha-
nisms of SARS-CoV-2 attachment, entry, and replication against which it may be possible to develop host-directed 
therapies that dampen viral infection and disease progression. Several of these SLiMs have now been validated to 
mediate the predicted peptide interactions.
INTRODUCTION
The coronavirus disease 19 (COVID-19) pandemic is caused by se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an 
enveloped, single-stranded RNA virus. It had infected more than 
68 million people and caused over 1.5 million deaths globally by 
mid-December 2020. SARS-CoV-2 belongs to the Coronaviridae 
family, whose members are common human pathogens responsible 
for the common cold, as well as for some emerging severe respirato-
ry diseases. Among them are the SARS-CoV and the Middle East 
respiratory syndrome coronavirus (MERS-CoV), the former of 
which caused over 8000 cases in 2003 with a fatality rate of ~10% 
and the latter caused about 2500 infections in 2012 with a fatality 
rate of 37% (1). Another coronavirus, infectious bronchitis virus 
(IBV), infects birds and has been used as a model in coronavirus 
research (2). SARS-CoV-2, like SARS-CoV (3), uses the angiotensin- 
converting enzyme 2 (ACE2) as a receptor (4–6) to attach to host 
cells. ACE2 is a single-pass type I membrane protein with a short 
cytosolic C-terminal region for which the functionality, however, is 
mostly unknown.
Earlier results show that the SARS-CoV-2 receptor-binding do-
main (RBD) of the spike protein interacts with ACE2 for cellular 
entry. In 2004, ACE2 was shown to be highly expressed in lungs by 
anti-ACE2 antibody staining (7). However, several 2020 papers us-
ing both antibodies and single-cell mRNA sequencing now find that 
there is very little ACE2 gene expression in normal lungs (8–11). 
This suggests that the ACE2 receptor is insufficient to establish se-
vere lung disease and that SARS-CoV-2 can bind other cell surface 
receptors on human lung cells. One group of candidate co-receptors 
are the integrins that bind a large variety of ligands harboring an RGD 
(Arg-Gly-Asp) sequence motif, as recent analysis of the RBD identified 
a possibly functional RGD motif (12).
Integrins are major cell attachment receptors, which are known 
to be targeted by a range of viruses—including HIV, herpes simplex 
virus-2, Epstein-Barr virus (EBV), and the foot and mouth disease 
virus (FMDV)—for cell entry and activation of linked intracellular 
pathways (13–15). Integrins are special types of receptors, as they 
propagate signals in both directions; extracellular ligands can induce 
cytoplasmic pathway activation, but intracellular interactions with the 
cytosolic tails can influence the structure of the ectodomains and hence 
ligand-binding affinity. The complexity of integrin signaling stems 
from the dimeric structure of integrins, as they are composed of two 
subunits,  and . For the RGD-binding integrins, the ligand-binding 
surface lies at the interface of the two integrin subunits, with both 
subunits making contacts with the ligand. These RGD motifs are 
recognized by at least 8 of the 24 human integrins, and the flanking 
residues next to the core RGD motif are known to play a decisive 
role in selectivity (16). Several viral proteins contain RGD (or RGD-
like) short linear motifs (SLiMs) for integrin modulation; in addi-
tion, not only some viruses can use integrins on the host cell surface 
but also HIV/SIV (simian immunodeficiency virus) can incorpo-
rate integrins into their own membranes for mediating interactions 
with the host (17). Therefore, integrins can potentially be targeted 
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at both the extracellular and the intracellular side to combat patho-
genic hijacking.
Viruses, as obligate intracellular entities, need to interfere with 
major cellular processes like vesicular trafficking, cell cycle, cellular 
transport, protein degradation, or signal transduction to satisfy 
their replication, enzymatic, metabolic, and transport needs (18). 
To achieve this, a large number of host processes are hijacked using 
SLiMs often located in intrinsically disordered regions to establish 
protein-protein interactions with host proteins or undergo post-
translational modifications (PTMs) such as tyrosine phosphoryl-
ation. For example, cellular signaling relies heavily on the use of 
SLiMs (19, 20). The low affinity and cooperativity of SLiM-based 
molecular processes allow reversible and transient interactions that 
can work as switches between distinct functional states and are reg-
ulated in both time and space (21,  22). Conditional switching of 
SLiMs, for example, through phosphorylation, can induce the ex-
change of binding partners for a protein, thus mediating molecular 
decision-making in response to signals reporting on the cell state 
(20). The Eukaryotic Linear Motif (ELM) resource (http://elm.eu.org/) 
is a dedicated database and exploratory server for over 280 manually 
curated SLiM classes with experimental evidence, each of them 
defined by a POSIX regular expression (23).
As explained above, a major strategy of viruses is to abuse the 
host system by using mimics of eukaryotic SLiMs to compete with 
extracellular or intracellular binding partners or to sequester host 
proteins (18). This dependence of viruses and many other patho-
gens on SLiM-mediated functions suggests that there is an opportu-
nity to drug the cell systems where these interactions are being 
hijacked (24). For example, tyrosine kinase inhibitors, often used in 
anticancer therapy, have shown promising coronavirus replication 
inhibition in infectious cell culture systems (2, 25–27). In the re-
mainder of the introduction, we will describe some of the major 
pathways hijacked by viruses to accomplish cell attachment, entry, 
and replication, which are suggested by our results to be relevant to 
SARS-CoV-2 infection.
Receptor-mediated endocytosis (RME) is a cellular import 
process triggered by cell surface receptor proteins, including any car-
goes attached to them, in which a large vesicular structure is assem-
bled entirely through cooperative low-affinity interactions of SLiMs 
and phospholipid head groups with their globular protein domain 
partners. The vesicles are strong and stable, yet flexible and dynam-
ically assembled and disassembled. The external triggering of sur-
face receptors (many of which have the YxxPhi or NPxY tyrosine 
sorting motifs) is transmitted across the plasma membrane, inducing local 
enzymatic modification of lipid head groups from phosphatidylinositol- 
4-phosphate (PI4P) to phosphatidylinositol 4,5-bisphosphate [PI(4, 5)
P2] by the PIPK1 kinase. The local enrichment of PI(4,5)P2 enables 
binding of domains such as ENTH in epsins that can begin to curve 
the membrane and assemble clathrin cages using their clathrin box 
motif and also attract additional adapter proteins via yet more SLiMs. 
In turn, additional sets of SLiM-bearing proteins stimulate the actin 
filament formation and attachment, necessary to fold and pull the 
invagination into the cytosol. Later, dynamin binds directly to PI(4,5)P2 
on the membrane to complete the scission process. Once in the 
cytosol, the clathrin-coated vesicles are soon dismantled and the 
contents are included into the early endosomes. [For recent reviews 
of the process, see (28–30).] Many viruses enter the cell via endocytosis, 
using many different cell surface receptors (31). Viruses such as 
HIV and hepatitis C virus depend on the recognition of more than 
one receptor for entry, but in many cases, the stoichiometry of re-
ceptor engagement is unknown. Coronaviruses can enter cells through 
different routes that include RME and cell-cell fusion (32). In the 
case of SARS-CoV, the main entry route is endocytic and depends 
on endosome acidification (33, 34). However, protease-mediated 
activation of the spike protein relieves the pH dependence of viral 
entry, indicating that acidification is not a requirement per se, but 
acts by inducing the endosomal cleavage of the spike protein re-
quired for viral fusion (35, 36). The spike protein is cleaved either 
by the transmembrane protease serine 2 (TMPRSS2) at the cell sur-
face or by cathepsin L within endosomes (37). The same entry route 
and proteases are used by SARS-CoV-2, and the use of endocytosis 
inhibitors indicates that the main entry route also seems to be endo-
cytic (4, 38).
Autophagy is an evolutionarily conserved process in eukaryotes 
with multiple cellular roles that include the regulation of cellular 
homeostasis through the catabolism of cell components, immune 
development, and the host cell response to infection through patho-
gen phagocytosis (39). Viruses have evolved mechanisms to block 
the host cell antiviral response and can further hijack autophagy 
components to promote their survival and replication. This can be 
done through viral mimicry of host proteins coordinating autopha-
gy or through the direct inhibition of the host autophagy machinery 
(40). Coronaviruses exploit the autophagy machinery through dif-
ferent mechanisms (41, 42). For example, MERS-CoV targets the 
BECN1 autophagy regulator for degradation, blocking the fusion of 
autophagosomes and lysosomes and protecting the virus from 
degradation (43). Coronaviruses repurpose cellular membranes to 
create double-membrane vesicles (DMVs) onto which the replication- 
transcription complex (RTC) is assembled, a process that involves 
recruitment of multiple autophagy components (41, 44, 45). DMVs 
in SARS-CoV-2 confine viral double-stranded RNA (dsRNA) con-
cealing the viral genome from the innate immune system (46). 
Betacoronavirus mouse hepatitis virus (MHV) RTCs assemble by 
recruiting LC3-I, a nonlipidated form of the autophagy-associated 
protein LC3 (microtubule- associated protein 1A/1B–light chain 3) 
(41, 47), and SARS-CoV RTCs also colocalize with LC3 (44). Proximity- 
based mass spectrometry on the MHV replication complex further 
revealed that the RTC environment repurposes components from 
the host autophagy, vesicular trafficking, and translation machiner-
ies (45).
In the present work, we identify a set of conserved SLiM candi-
dates in the ACE2 and integrin proteins, which are likely to act in 
the cell entry system of SARS-CoV-2 and provide molecular links to 
understand how the virus recognizes target membranes, enters into 
cells, and repurposes intracellular membrane components to drive 
its replication. These molecular links might provide previously un-
identified clues toward drugging SARS-CoV-2 infections. We first 
focus on the extracellular SLiMs, before moving across the mem-
brane to examine the cytosolic potential of the receptor tails. In a 
coincidently published paper, experimental testing of several motifs 
in the receptor tails is presented (48).
RESULTS
Extracellular receptor interplay and viral hijacking 
in the ACE2/integrin system
The identified RGD motif in the spike protein marks integrins as can-
didates for acting as co-receptors for SARS-CoV-2 entry. However, 
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similarly to most SLiMs, the integrin-binding RGD motif has a low 
sequence information content, and the chance of random occur-
rence in protein sequences is relatively high. Therefore, the mere 
presence of an RGD motif in a sequence is not a strong indication of 
actual integrin binding. However, there are several features that 
make the spike-integrin interaction via the RGD motif plausible, 
including sequence- and structure-level information, gene expres-
sion profiles, the presence of accessory motifs, and protein-protein 
interactions. In the next sections, we review how this information 
gives credibility to the functional nature of the spike protein RGD 
as an integrin-binding motif and, more generally, to the existence of 
integrin hijacking by SARS-CoV-2.
The evolution of integrin-binding motif candidates within RBDs 
in the spike protein highlights that while the RGD motif is not 
conserved, the integrin-binding capacity might have evolved conver-
gently in several betacoronaviruses. Owing to the high rate of re-
combination in coronaviruses (49), it is challenging to build proper 
phylogenies to trace their evolution. However, simply aligning 
homologs of the RBD from the Betacoronavirus genus (Fig. 1A) 
already shows that the RGD motif candidate is located in a locally less 
conserved region, hinting at the rapid evolvability of the site. The 
closest known homolog of SARS-CoV-2 is the RatG13 bat corona-
virus containing TGD instead of RGD, which is incompatible with 
integrin binding. However, while the RGD motif itself is not con-
served, several other members of the Betacoronavirus genus harbor 
other possible integrin-binding motifs. SARS-CoV and several of its 
close homologs, such as BM48-31/BGR/2008, contain KGD at this 
site. KGD can bind integrin as part of disintegrin binding, such as in 
the snake venom barbourin (50), but because disintegrins lacking 
KGD also bind integrin (51), and there is no evidence of KGD bind-
ing independent of disintegrins, we think that SARS-CoV KGD is 
less likely to be an active integrin ligand.
Considering more distant homologs of SARS-CoV-2, it becomes 
evident that the presence of an RGD/KGD site is not a universal 
feature of betacoronaviruses. The RBD of a moderately related 
Rousettus bat coronavirus does not contain any of the three residues 
of the RGD (Fig. 1B). However, other even more distant coronavirus 
sequences show a different potential integrin targeting motif at the 
same site. OC43 is a betacoronavirus that is one of the pathogens 
causing the common cold. Several OC43 RBD sequences show an 
NGR motif in nearly the same position as the SARS-CoV-2 RGD. 
NGR is an integrin interaction motif that becomes active upon the 
nonenzymatic natural deamidation of the asparagine residue pre-
ceding a glycine to isoaspartic acid, forming an l-isoDGR site, 
which can recognize several v integrins, as well as integrin 51 
(52). The parallel evolutionary emergence of potential integrin- 
binding motifs at this location indicates that, despite the lack of 
conservation at the site, the SARS-CoV-2 RGD motif might be 
functional.
Normally, the functional importance of a protein region cor-
relates with its conservation. Checking for sequence variances in the 
SARS-CoV-2 spike protein RGD motif across isolates showed that 
all 8841 (when checked on 9 June 2020) high-quality full spike pro-
tein sequences in GISAID (Global Initiative on Sharing Avian 
Fig. 1. The RGD motif of the SARS-CoV-2 spike protein. (A) Multiple sequence alignment of a part of the SARS-CoV-2 spike RBD region using homologous sequences 
from betacoronaviruses of various evolutionary distances and showing the location of potential integrin-binding motifs in black. Virus names together with the host or-
ganisms, UniProt accessions (*or GenBank accession in the case of RatG13), and sequence region numberings are shown on the left side of the alignment. The location of 
the region shown in the alignment is indicated in a representative diagram of the spike protein, together with the location of the RGD motif and the region responsible 
for ACE2 binding. (B) Neighbor-joining tree of the multiple sequence alignment, with this particular set of sequences containing the potential high affinity, low affinity, 
and reverse integrin-binding motifs (RGD, KGD, and NGR) shown in red, orange, and green boxes, respectively. Only the sequence regions shown in (A) were used in the 
calculation of the tree. (C) Structure of the SARS-CoV-2 RBD as seen in the ACE2-bound form (PDB:6m17). The RGD motif is shown in red sticks. Regions in direct contact 
with ACE2 are shown in blue. Residues with missing atomic coordinates (indicating flexibility) in the unbound trimeric spike protein structures (PDB:6vsb, 6vxx, and 6vyb) 
are shown in transparency. Alignment and tree were prepared in Jalview (226) with Clustal colors. Structure was visualized using UCSF Chimera (228).
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Influenza Database) (53, 54) contain the RGD region together with 
the two flanking residues. While normally a fully conserved site 
would indicate functional importance, the full spike protein se-
quence shows very little variation among isolates, with some standard 
conservation scores (55) giving a value of 1 uniformly across the whole 
spike protein sequence.
The structural features of the SARS-CoV-2 spike protein RGD 
motif are compatible with integrin binding. At the time of reporting 
the RGD motif, no SARS-CoV-2 spike protein structures were 
available, so the authors used structural homology modeling to de-
termine that the RGD motif is surface accessible (12). Since then, 
several RBD structures have been determined, in both unbound 
(5, 56) and ACE2 complexed forms using electron microscopy (57) 
and X-ray diffraction (58), allowing for the direct structural assess-
ment of the possibility of binding to integrins. In the sequence, the 
RGD motif and the ACE2 binding site do not overlap (see the sche-
matic in Fig.  1A); however, in the RBD structural fold, the RGD 
motif is largely surrounded by residues binding to ACE2 (Fig. 1C). 
This indicates that ACE2 binding obscures the RGD motif and the 
two interactions would be mutually exclusive on a single copy of the 
RBD. However, in the uncomplexed structures, the residues that 
surround the RGD site are flexible, whereas the RGD motif is sur-
face accessible and is in the appropriate -turn conformation for 
binding integrins. Thus, without ACE2, the interaction with integ-
rins is not sterically blocked.
The spike protein is heavily glycosylated in its functional form. A 
comprehensive glycosylation analysis of the spike protein showed 
that the ACE2 binding site can be partially shielded by structurally 
nearby glycans located at Asn165, Asn234, and Asn343. However, the 
spike protein RBD has two alternative conformations, and this shield-
ing by glycans only happens in the “down” conformation. Similarly, 
the glycans do not shield the RGD motif in the binding- competent 
“up” conformation (5, 59), and therefore, the RGD is accessible for 
interaction.
Given that the spike protein exists as a trimer on the virion 
surface, different copies of the RBD can, in theory, interact with 
ACE2 and integrins at the same time. Under the right structural 
settings, even two copies of the RBD in the same spike protein 
trimer can bind to ACE2 and integrins. The feasibility of such an 
interaction depends on the spatial orientation of the integrin:ACE2 
complex, which has been shown to form naturally (60). Although 
we know that the interaction is between ACE2 and the  subunit 
of the integrin dimer, there is no solved structure of the ACE2- 
integrin complex. However, further structural consideration may 
indicate whether the spike-ACE2 and the spike-integrin interac-
tion can coexist within the same spike protein trimer (fig. S1). The 
ectodomains of both ACE2 and integrins in the open conforma-
tion are roughly the same length measured from the membrane, 
being about 100 Å, depending on the conformation of the integrin 
dimer [based on available structures; PDB:6m17 (57) and PDB:6avr 
(46)]. This means that the RGD-binding site of integrins and the 
RBD-binding regions of ACE2 are relatively close in space. In ad-
dition, in the ACE2 binding- competent up conformation of the 
RBDs, the distance between pairs of RBDs is about 66 Å [based on 
the structure PDB:6x2b reported in (61)]. Thus, the simultaneous 
binding of an integrin dimer and an ACE2 dimer to the same 
spike protein trimer would orient ACE2 and the integrin to have 
the correct distance and orientation for the integrin  subunit to 
bind ACE2.
The sequence and structure context of the RGD motif can indi-
cate possible target integrins. RGD motifs are recognized by several 
integrins, and specificity is determined mostly by the flanking 
residues of the core motif. As evidenced by crystallized integrin 
dimer-ligand complexes, the residue preceding RGD is in contact 
with the  subunit, whereas the residue after the core motif interacts 
with the  subunit. The immediate context of the SARS-CoV-2 
RGD motif is 402-IRGDE-406 (Fig. 1A), which can give an indica-
tion about possible integrin targets. IRGD can be found in several 
native integrin-binding partners, including FREM1 (62), MFAP4 
(63), and IGFBP1/2 (64,  65). These extracellular matrix proteins 
target integrins with v, 5, and 8 subunits. RGDE is present in 
the native human integrin ligands TGFBI, osteolectin, collagen 
-1(VI) chain, PSBG-9, and polydom, and in vitro and in vivo bind-
ing studies of the specificity profiles of these proteins (66–71) high-
lighted a post-RGD Glu to be efficient in binding to 1, 2, and 3 
integrin subunits. Correlating these preferences with possible 
- and -integrin subunit pairings points to the most likely candidate 
target integrins for SARS-CoV-2 being v1, v3, 51, and 81. 
However, in vivo and in vitro integrin-binding studies have indicated 
that various v and 51 integrins share a large overlap in binding 
specificity for ligands, and therefore, any of these integrins might 
play a role in SARS-CoV-2 cell attachment and infection.
Most RGD-binding integrin dimers recognize the partner RGD 
motif in a long loop conformation that fits into the deep binding 
pocket of the receptor (fig. S2A), including the integrin candidates 
identified by the RGD-flanking residues. However, available struc-
tures highlight that v6 integrins have a different structural preference 
in their ligands. In this binding mode, the ligand is only in contact 
with the integrin  subunit via the Arg residue of the RGD motif. 
Therefore, the  subunit plays little role in specific ligand recognition. In 
contrast, the region following the RGD motif adopts an  helix and 
binds to the -integrin subunit (fig. S2B). In most known cases, this 
interaction is stabilized by two small hydrophobic residues fitting into 
two hydrophobic pockets on the surface of integrin 6, establishing 
contacts with the three specificity-determining loops (72), conforming 
to a pattern of xRGDφxxφ, where φ indicates a hydrophobic resi­
due and x indicates any residue. This binding mode is known to be used 
by the growth factors transforming growth factor–1 (TGF-1) and 
TGF-3 (72), and it is also mimicked by the cell attachment loop of 
the FMDV for cell entry (73). In its unbound state, the RGD motif 
of the SARS-CoV-2 spike protein RBD resides in a loop, followed by 
a helical structure containing two small hydrophobic residues, rem-
iniscent of bound structures of v6 ligands (fig. S2C). While the 
RBD is stabilized via three disulfide bridges, the RGD motif– 
containing region is on the far side of the domain. In addition, this 
region—together with the ACE2 binding site—has the highest aver-
age B-factor of the whole spike protein trimer (fig. S2D), hinting at 
a possible structural rearrangement to accommodate the binding.
A major difference between TGF-–type ligand and the RBD se-
quence is that RBD contains an extra residue between the RGD and 
the two hydrophobics, conforming to a pattern of RGDxφxxφ in-
stead. On the basis of current knowledge, it is unclear how this 
would influence integrin binding; however, there are known v6 
ligands that also deviate from the TGF- subtype. Fibrillin-1 con-
tains an integrin-binding region with the sequence RGDNGD-
TACSN, and it is a known ligand for integrins 51, v3, and v6 
(74). The deviation from the canonical TGF-–type motif is possi-
bly a compromise between the—hitherto undescribed—specificity 
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determinants of the three integrins, resulting in binding to several 
receptors with reduced affinity.
Motif-domain interactions are typically under heavy spatio- 
temporal regulation. Hence, the SARS-CoV-2 RBD-integrin binding 
can only occur if the possible target integrins are expressed on the 
infected host cells. Integrins 51 (75) and v3 (76–78), at least, 
have been observed in lung epithelial cells—the primary cells of in-
fection in the lung—and are implicated in the emergence and pro-
gression of various diseases, including emphysema, non–small cell 
lung cancer, and mechanical injury of the lungs (79). SARS-CoV-2 
infection has been observed to cause damage in various other tis-
sues as well, including the heart, blood vessels, liver, and kidney 
(80). v integrins are near ubiquitous in major human tissues (81) 
and have been observed in all organs with observed damage from 
SARS-CoV-2 infections.
There are several other factors that point to an interplay between 
ACE2 and various integrins under normal cellular conditions. It 
has been shown that in heart tissues, ACE2 is able to bind the 1 and 
5 subunits of integrins in an RGD-independent manner, enhanc-
ing cell adhesion and regulating integrin signaling via the focal ad-
hesion kinase (FAK) (60). It is unclear whether ACE2 interacts with 
integrins from the same cell, suppressing integrins by locking them 
in an inactive conformation, or adherent cells, acting as a direct in-
hibitor of integrins. However, the functional link indicates that in-
tegrins and ACE2 are expressed on the surface of the same cells in 
certain tissues, further corroborated by large-scale expression data 
(81). Furthermore, the RGD independence of the interaction means 
that while ACE2 and integrins are in complex, the RGD-binding 
site of the integrin is unoccupied, leaving it available for a potential 
interaction with a spike protein trimer.
Apart from the known interplay between ACE2 and integrins, 
there are additional features that indicate an even tighter cross-talk 
between the two receptors. RGD-mediated interaction to integrins 
is metal-mediated (via divalent cations like Mg2+ or Mn2+), and all 
integrins have a so-called “metal ion–dependent adhesion site” 
(MIDAS) motif (DxSxS) (82). The integrin MIDAS structural motif 
is located near the ligand-binding site on the  subunit and is essen-
tial for binding, as side chains belonging to the motif and an acidic 
residue from the ligand coordinate the metal ion together (83). 
ACE2 also has a similar DxSxS motif (see Table 1) that might facil-
itate interactions with ligands that are recognized by integrins, cre-
ating an overlap between the ligand-binding profiles and regulation 
of the two receptors. In the known structures where spike protein is 
bound to ACE2, the RGD motif is not in contact with the ACE2 
MIDAS (57). However, the MIDAS motif is highly conserved across 
species (see Fig. 2) and surface exposed. The conserved ACE2 
MIDAS motif partially overlaps with a semiconserved NxT glycosyla-
tion motif, and the attached carbohydrate is present in solved ACE2 
structures (57). This glycosylation does not directly affect the 
MIDAS’s acidic residue, which might play the main role in ligand 
binding. Consequently, the ACE2 MIDAS may still be involved in 
mediating an interaction with an RGD-like motif, potentially serv-
ing as a parallel mechanism for binding the spike protein.
Extracellular proteases are native modulators of cell surface re-
ceptors, and the SARS-CoV-2 spike protein uses these proteases to 
enhance infection. ACE2 and several integrin subunits require pro-
teolytic cleavage for biological activity. Integrin subunits 3, 5, 6, 
and v are cleaved by furin or furin-like proprotein convertases 
(PCs) during maturation (84, 85). Nearly all PCs contain an RGD 
motif, and while its role in integrin binding is not clear, the motif 
has been shown to be required for proper functioning for several PCs 
(86–88). The SARS-CoV-2 spike protein contains a furin-like cleav-
age site that is absent from closely related spike proteins, immediately 
following the RBD (89). This cleavage is essential for infection of 
human lung cells (90) and results in increased virulence. A structural 
effect of the cleavage might be to allow greater movement of the RBD, 
potentially aiding in exploring a larger space around the RBD-binding 
region of ACE2. The cleavage by furin has also been shown to create 
a new SLiM in the spike protein, conforming to the C-end rule 
([RK]xx[R]$ CendR motif where $ indicates the C-terminus of the 
protein, ELM:LIG_NRP_CendR_1; see Table 1) and mediating attach-
ment to host cell surface via neuropilin-1 and neuropilin-2 (NRP1 
and NRP2) (91). Similarly to ACE2, NRP1 physically interacts with 
integrin 1 and regulates integrin signaling (text S1 and fig. S8, A 
and B) (92, 93). The binding of NRP1 to peptide C termini may be 
associated with cooperative heparin binding (94); the SARS-CoV-2 
S1/S2 cleavage site contains a heparin-binding motif (RRxR) that may 
partly explain the higher binding affinity of the SARS-CoV-2 spike 
protein for heparin, compared with SARS-CoV and MERS (95), and 
the inhibition of SARS-CoV-2 infection by heparin (96).
ACE2 is cleaved by several proteases, including TMPRSS2 (97). 
ACE2 binds to TMPRSS2, forming a receptor-protease complex 
(98). TMPRSS2 is also known to cleave the spike protein of both 
SARS-CoV and MERS-CoV (99), augmenting their entry into the 
host cell (97). Furthermore, similar results have been found for 
SARS-CoV-2, where TMPRSS2 was found to be fundamental for 
cell entry (4). This dependence is most probably twofold: On one 
hand, TMPRSS2 is needed for ACE2 activation; on the other hand, 
SARS-CoV-2 spike protein also contains a TMPRSS2 cleavage 
site (100).
SLiM candidates in the ACE2 receptor intrinsically 
disordered tail
Recent structural analysis provided experimental evidence that the 
ACE2 tail is intrinsically disordered across the region following the 
transmembrane helix (residues 769 to 805) (57), as is also predicted 
from sequence analysis. The ACE2 sequence (UniProt: ACE2_ 
HUMAN) was entered in the ELM server (23) and returned several 
relevant candidate SLiMs in the short cytosolic C-terminal tail. Be-
cause SLiMs are so short, it is difficult to obtain reliable results in 
sequence searches. Contextual information, including cell com-
partment localization and functional relevance, is important in 
deciding whether a motif candidate is worth testing experimen-
tally (101). Furthermore, in intrinsically unstructured protein se-
quences, amino acid conservation is usually indicative of functional 
interactions. Therefore, an alignment was prepared of vertebrate 
ACE2 proteins. The deepest diverged organism with a sequenced 
ACE2 gene is the hagfish, a jawless fish included in the subphylum 
Vertebrata, although it lacks vertebrae (102). All of the detected 
motif matches in human ACE2 [shown in Table 1 together with 
potential binding partner domains defined using Pfam (103) and 
InterPro (104)] were conserved in mammals, most were con-
served with birds and mammals and some were conserved with 
extant reptiles (Fig. 3). These groups diverged from one another 
>300 million years ago (105). However, whereas the NPY motif, for 
example, is absent in reptiles, it is present in bony fish ACE2 se-
quences and also in the hagfish, indicating that NPY has been lost in 
the reptile lineage. The hagfish sequence shares all of the candidate 
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motifs present in the human ACE2 tail, although it is >500 million 
years since their lineages diverged (102). In addition to the strong 
evolutionary conservation of these candidate motifs, their functional 
contexts are also biologically coherent, involving signaling by 
tyrosine kinases, endocytosis, autophagy, and actin filament in-
duction (Table 1). In the following subsections, we briefly summa-
rize each of the conserved motifs and their possible role in the 
viral entry mechanism.
The ACE2 tail contains a candidate YxxPhi endocytic sorting 
signal. The YxxPhi motif binds the 2 subunit (UniProt: AP2M1_
HUMAN) of the endocytosis AP2 adaptors by -augmentation 
(106). It is found in numerous cell surface receptors that have in-
trinsically disordered C-terminal tails (107). A small selection is 
listed in the database entry ELM:TRG_ENDOCYTIC_2, and while 
the motif has not been validated in ACE2, it is highly conserved 
(Fig.  3). When the Tyr is phosphorylated, this motif becomes an 
SH2-binding site, while in the apo form, it binds the 2 adapter. 
Therefore, this motif can operate as a molecular switch. The residue 
following the Tyr makes a -strand interaction and therefore can-
not be a proline (PDB:1bxx). The phi position requires a bulky hy-
drophobic residue. The motif pattern can be represented by the 
regular expression Y[^P].[LMVIF], and this motif is conserved in 
ACE2 of all mammals except monotremes. Thus, the mammalian 
ACE2, which internalizes the coronavirus, has a SLiM candidate for 
internalization appropriately located within its cytosolic tail. The 
ACE2 tail sequence was found to bind with moderate affinity to 
AP2 2 subunit (48) well within the 30 to 100 M range of biologi-
cally relevant affinities.
The region encompassing the YxxPhi motif overlaps with a can-
didate SRC homology 2 (SH2) domain–binding motif (Fig. 3) that 
is created upon phosphorylation of Tyr781. SH2-binding motifs are 
characterized by an invariant phosphotyrosine (pY) that is created 
following tyrosine kinase activation and allows binding to more than 
100 types of SH2 domains present in human proteins (108). The pY 
residue is accompanied by additional binding determinants that fre-
quently involve hydrophobic residues at the pY + 3 position, but can 
also involve other combinations, such as Asn at pY + 2 in Grb2-specific 
SH2 motifs or hydrophobic residues at pY + 4  in STAP-1 SH2 
motifs (112; 110). Most SH2 motifs are also characterized by the 
exclusion of residues at certain positions following the pY, and in 
general, SH2-binding motifs show a high degree of cross-specificity 
(112) (109), limiting the power of bioinformatics predictions.
Cell culture infection assays with different coronaviruses, in-
cluding SARS-CoV, have shown susceptibility to tyrosine kinase 
inhibitors, indicating the involvement of host tyrosine phosphoryl-
ation (25; 26; 27; 2). The sequence found in ACE2 (781-YASID-785) 
matched the regular expression (Y)[DESTNA][^GWFY][VPAI]
[DENQSTAGYFP] defined in the ELM database for the SH2 do-
main present in NCK1/2 proteins, which belong to the class IA SH2 
domains (110). No other SH2 entry catalogued in ELM matched the 
Table 1. Known and predicted SLiMs in SARS-CoV-2 host-entry interactions. Previously identified motifs are marked with (✓). Regular expressions follow 
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tail. Proteins known to contain this motif are listed in entry ELM:LIG_ 
SH2_NCK1_1. We have since learned that an ACE2 phosphorylated 
Tyr781 (pTyr781) tail peptide does not bind to NCK1 (48). Upon re-
examination of the SPOT arrays in (111, 112), we noted that the 
strong preference at pY + 3 is for Val and Pro. While Ile is tolerated 
at pY + 3 in the context of the high-affinity EPEC Tir (enteropathogenic 
Escherichia coli translocated intimin receptor) sequence (111), it is 
not tolerated in the context of random peptide pools (112). This 
would indicate that NCK can only tolerate a weak Ile residue at 
pY + 3 when a strong residue such as Glu and Asp is found at pY + 1, 
such as Asp in EPEC Tir. The presence of the weak aliphatic residue 
Ala at pY + 1  in ACE2 would explain the lack of binding for the 
ACE2 tail motif. This evidence indicates that the ELM pattern needs 
correcting to allow only one weak amino acid at either of pY + 1 or 
pY + 3 in the regular expression.
Other class 1A SH2 domains with a strong preference for Ile at 
the +3 position in SPOT array include the SH2 domains of the SRC 
family kinases (SFKs). A regular expression for SRC family SH2 do-
mains allowing for weak/strong residues +1 and +3 positions and 
compatible with the SPOT arrays could be ((Y)[DE][^KRHG] 
[DESTAPILVMFYW][^KR])|((Y)[NQSTAILVMFY][^KRHG]
[ILV][^KR]) (Table 1). This pattern matches the ACE2 tail. The 
ACE2 YASID sequence has a weak Ala at pY + 1, neutral Ser at 
pY + 2, and strong Ile and Asp at pY + 3/+4, making this a plausible 
motif for binding SFKs. Because all human cells have at least one 
SFK, and they are involved in regulating endocytosis and actin fila-
ment formation (113–115), their SH2 domains are plausible candi-
dates for binding the ACE2 tail. For example, Abl kinases have 
specialized cytoskeletal remodeling capacity mediated through their 
actin binding and actin bundling domains (113), while SRC enhances 
receptor endocytosis and focal adhesion (FA) remodeling through 
the phosphorylation of Eps8 and dynamin2 (115). We also turned 
to the ModPepInt server that uses unsupervised learning tech-
niques to train SH2- binding motif prediction. ModPepInt has 
models for 51 SH2 domains (116). A run of the ACE2 tail sequence 
returned best matches with several nonreceptor tyrosine kinases, 
most harboring class IA SH2 domains that largely overlap with 
expectations from the SPOT arrays (the kinases Abl1/2, BLK, FGR, 
FRK, HCK, LCK, SRC, FYN, and TEC) plus other predicted binders, 
such as the kinase FES and the adaptor proteins GRB10 and GRB14 
(table S1). Kliche et al. then tested the revised SH2 motif assignment 
to the SFKs, measuring a low micromolar affinity for the Fyn SH2 
domain with the tyrosine- phosphorylated ACE2 peptide (48).
The residues present at pY + 1, pY + 2, and pY + 4 should rule 
out that the ACE2 YASID motif can be a strong Grb2, CRK, and 
STAP-1 SH2 domain binder, and binding to SH2 domains in the 
transcription factors signal transducer and activator of transcrip-
tion 1 (STAT1), STAT3, and STAT5 is also unlikely due to the lack 
of adequate specificity determinants. However, other SH2 domains, 
particularly ones with low observed specificity (e.g., PTPN11_N, 
PLCgamma1_C, and SH2D1A), could be recruited by ACE2 when 
there is coexpression in the same cell type. Experimental validation 
will be required to test these hypotheses.
Tyr781 in ACE2 also overlaps with a candidate phosphorylation- 
independent NPY IBAR-binding motif (ELM:LIG_IBAR_NPY_1). 
This motif was initially described in the bacterial secreted protein 
Fig. 2. Alignment of ACE2 illustrating conservation of the MIDAS motif. Multiple sequence alignment of a part of the ACE2 extracellular domain using 25 homologous 
sequences from different vertebrate lineages (mammals, birds, reptiles, and fish) and showing the conservation of the Dx[ST]xS motif as well as an NxT glycosylation site 
(main residues displayed above). A red box marks the conservation range of the MIDAS motif in all sequences but the hagfish. Organism names, UniProt IDs (UniParc for 
hagfish), and sequence numberings are listed on the left side of the alignment. The location of the region shown in the alignment is indicated in a representative diagram 
of the ACE2 protein. Figure was prepared with Jalview using Clustal colors. TM, transmembrane; C-ter, C-terminal.
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Tir from pathogenic strains of Escherichia coli, such as enterohaem-
orrhagic E. coli (EHEC). The NPY tripeptide recognizes and binds 
with a 60 M affinity to inverse Bin-Amphiphysin-Rvs (I-BAR) do-
mains in adaptor proteins like insulin receptor substrate protein of 
53 kDa (IRSp53) and its homolog insulin receptor tyrosine kinase 
substrate (IRTKS) (117, 118). I-BAR domains bind to the plasma 
membrane to favor weak membrane protrusions, and the preference 
of I-BAR domains for negative membrane curvatures enables a pos-
itive feedback loop that can result in the formation of lamellipodia, 
filopodia, and other types of membrane protrusions (119–121). 
IRSp53 and IRTKS are modular proteins that contain SH3 domains 
that, in turn, recognize PxxP SLiMs in actin filament regulators like 
Mena, Eps8, and mDia1 (122), resulting in the formation of mem-
brane protrusions through actin filament formation (117, 119–121). 
Moreover, IRSp53 has an additional Cdc42-binding motif that can 
result in a direct neural Wiskott-Aldrich syndrome protein activa-
tion (122). During EHEC infection, the bacteria use the NPY motif 
in the transmembrane protein Tir to recruit IRSp53 (117). IRSp53 
acts as a scaffold to localize the injected bacterial protein EspFU to 
the bacterial attachment site, cytosolic side, through the binding of 
a PxxP motif in EspFU to the IRSp53 SH3 domain. Through the 
use of the same helical SLiM present in NCK (ELM:LIG_GBD_
CHELIX_1), EspFU acts as a potent Wiskott-Aldrich syndrome 
protein activator, inducing the actin polymerization that contrib-
utes to the pedestal formation characteristic of EHEC infections 
(123, 124). The NPY SLiM, although not yet experimentally validat-
ed in any human protein, is potentially functional in proteins like 
SHANK2 or the microtubule-binding CLIP-associating protein 1 
(CLASP1), based on protein conservation and functional associa-
tion (118). The putative NPY motif in ACE2 is conserved in all an-
alyzed mammalian and bird homologs (Fig. 3), suggesting a direct 
interaction with host I-BAR–containing proteins such as IRSp53 or 
IRTKS, which are expressed in lung tissues (81).
The I-BAR domain–binding motif in the cytosolic region of 
ACE2 could be relevant for SARS-CoV-2 infection in the following 
scenario. During viral cell entry, the NPY motif could recruit 
I-BAR–containing proteins such as IRSp53 or IRTKS, resulting in 
membrane protrusion formation that could be exploited for viral 
entry or in cell to cell transmission. It is known that the hijack of the 
filopodia formation network is beneficial for the entry and spread-
ing of many enveloped viruses (125), but whether this process is 
active during coronavirus infection is still unclear. A second route 
might cooperate with the NPY motif in the recruitment of actin cy-
toskeleton components. A direct interaction between the SARS-
CoV spike protein cytosolic side C-terminal domain and the ezrin 
FERM (4.1 protein, ezrin, radixin, moesin) domain can occur during 
the opening of the viral fusion pore and has been proposed to restrain 
viral infection (126). Ezrin is a protein involved in cell morphology and 
apical membrane remodeling that acts as a membrane-cytoskeleton 
linker. Ezrin recruits F-actin through its C-terminal domain and 
can also bind to IRSp53 located at negatively curved membranes 
(127, 128), suggesting that while the NPY motif acts at earlier stag-
es of viral attachment, the spike protein–Ezrin interaction might 
work during or after viral fusion, to promote the recruitment of 
actin-regulatory components to viral fusion sites.
Apart from the endocytic sorting signal, the SH2 binding, and 
the IBAR-binding motif, Tyr781 is also part of an LC3-interacting 
region (LIR) autophagy motif candidate (Fig. 3). Autophagy, the 
recycling of cellular material, is vital for cellular homeostasis. Many 
pathogens must control the autophagy response to establish productive 
Fig. 3. Alignment of ACE2 illustrating conserved motifs in the cytosolic C-terminal tail following the transmembrane helix. Multiple sequence alignment of ACE2 
transmembrane and C-terminal regions using 25 homologous sequences from different vertebrate lineages (mammals, birds, reptiles, and fish) and showing their motif 
conservation. The names (bold) and key residues of the motifs are displayed above the alignment (ɸ stands for a bulky hydrophobic residue), including a conserved tyro-
sine (bold) and excluded positions (red and crossed). Red boxes mark the conservation range of the PDZ-binding motif (PBM) (all sequences) and NPY motif (in mammals, 
birds, and some fish). Organism names, UniProt IDs (UniParc for hagfish), and sequence numberings are listed on the left side of the alignment. The location of the region 
shown in the alignment is indicated in a representative diagram of the ACE2 protein. Figure was prepared with Jalview using Clustal colors.
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infection (39). It has been shown that coronaviruses, including those 
that infect humans, subvert autophagy components to promote 
viral replication at DMVs associated to the RTC (43, 47, 129, 130). 
The LIR motif is required for the interaction of a target protein with 
autophagy-related protein Atg8 in yeast, or its homologs LC3 and 
GABARAP in human, to facilitate autophagy of the target via the 
autophagosome (131). The LIR motif has been catalogued in the 
ELM resource entry ELM:LIG_LIR_Gen_1, and ELM detected a 
candidate motif in the human ACE2 cytosolic tail sequence (Fig. 3). 
After the LIR motif was annotated in ELM, a more recently solved 
LC3-LIR structure (PDB:5cx3) showed that the interacting peptide 
is longer, with one or two additional hydrophobic interactions 
(132). LIR enters a hydrophobic groove bordered by positively 
charged residues. A core [WFY]xx[ILMV] enters the deepest part 
of the groove. On either side of the core, the interacting residues 
can be flexibly spaced. The core must be preceded by a negatively 
charged residue (which might be enabled by phosphorylation). 
Furthermore, the motif core is followed by a flexibly spaced hy-
drophobic residue. There is often a negatively charged residue 
preceding this hydrophobic position: It can make favorable inter-
actions with counter charges but is not an absolute requirement, 
so is not included in the revised motif pattern. On the basis of the 
structure (PDB:5cx3) and some SPOT arrays (132–134), the updated 
regular expression [EDST].{0,2}[WFY][^RKP][^PG][ILMV].{0,4}
[LIVFM] matches the motif instances annotated in ELM. This 
revised motif is conserved in the mammalian ACE2 cytosolic tail 
as well as hagfish and ghost shark, but not in birds, reptiles, or 
bony fish. The ACE2 LIR motif candidate can potentially enable 
the incoming coronavirus to attract autophagy elements such as 
LC3 to the structures where the virus replicates and assembles. In 
line with this, a nonlipidated form of the LC3 protein has been 
shown to be associated with the RTCs of MHV and SARS-CoV 
(41, 44, 47). This brings up the interesting possibility that ACE2 
remains associated with the membranous structures where SARS-
CoV-2 replicates at later infection stages, assisting in the repurposing 
of autophagy components required for viral replication. Techni-
cal issues hampered the comprehensive testing of phosphorylated 
ACE2 peptide sequences containing the LIR candidate, but the un-
phosphorylated peptide did not show meaningful binding (48). 
However, phosphorylation of Ser783 seems to induce a weak bind-
ing with MAP1LC3A and GABARAPL2 domains, albeit with affin-
ities not reaching physiological relevance (48). So far, the evidence 
is not enough to support LIR functionality but perhaps multi- 
phosphorylation and/or a longer tail sequence could deliver a 
stronger interaction.
The ACE2 tail region C-terminal to the overlapping motifs cen-
tered around Tyr781 contains two additional motif candidates. The 
first such candidate is an apoPTB domain-binding motif. Certain 
members of the large PTB domain family were initially discovered 
to bind to phosphorylated NPxY motifs, hence the designation 
“phospho-tyrosine binding domain” (135). The NPxY motifs in 
cytosolic tails of receptors, including integrins, are regarded as en-
docytosis sorting signals (107). It was later discovered that PTB do-
mains in the endocytic internalization adapter protein Dab1 could 
also bind nonphosphorylated Nxx[FY] motifs (apoPTB motif) and 
that this might be the case for the majority of PTBs (136). Repre-
sentative receptors with apoPTB motifs are in the database entry 
ELM:LIG_PTB_Apo_2. The core Nxx[FY] motif is conserved in all 
the vertebrate ACE2s (Fig. 3). For the Dab1 endocytic adapter class 
of apoPTB motifs, there is a hydrophobic requirement two residues 
before the Asn. In ACE2 of fishes such as the hagfish and coelacanth 
(Latimeria chalumnae), the residue is hydrophobic (Fig. 3), suggest-
ing that this motif is present. However, in most other species in-
cluding human, Glu predominates at this position: Therefore, if this 
notably conserved Nxx[FY] is an apoPTB motif, it should then bind 
a PTB protein other than the Dab1 class. The apoPTB motif binds 
as a short -strand (-augmentation) followed by a -turn. Proline 
is rejected at the first position of the motif, which is a strand-forming 
residue, and therefore, the minimal regular expression for this motif 
is [^P].N..[FY]. As with the phosphorylated versions, the apo-motifs 
are tightly connected to endocytosis (136). The conservation of this 
motif in the homologous position of the cytoplasmic chain of the 
partially collinear collectrin protein (UniProt: CLTRN_HUMAN; 
fig. S3) indicates that this motif instance has an even earlier evolu-
tionary origin than the origin of ACE2 itself, hinting at a key role in 
internalization. As expected, because the specificity is not yet de-
fined, Dab1 and four other tested PTB domains did not bind to the 
ACE2 tail region (48). A poorly soluble sorting nexin 17 (SNX17) 
FERM domain was found to bind with ≈100 M affinity, providing 
an ambiguous result.
The very C-terminal region of ACE2 contains a TxF$ PDZ-binding 
motif (PBM) candidate. Among other motif-binding modules, PDZ 
domains come in great abundance in human and other multicellular 
animals (137). PDZ domains take part in a variety of biological pro-
cesses including cellular signaling and activity at the neuronal 
synapse (138). These domains bind by -strand augmentation to 
SLiMs that are called PBMs, most commonly known to be found in 
the C terminus of fully or partially disordered proteins. These in-
teractions are widely studied and their link to various diseases and 
infections has been previously established (139). A PBM candidate 
is also found in the very C terminus of the cytosolic tail of all verte-
brate ACE2 proteins (Fig. 3). Motifs following a pattern [ST].
[ACVILF]$ are a common PBM variant, described in the ELM 
resource entry ELM: LIG_PDZ_Class_1. There are multiple func-
tional examples of this motif. However, in the ACE2 protein, the 
matching sequence has not been characterized. Because the tail of 
ACE2 is facing the cytosol, it is available to interact with PDZ do-
mains with the appropriate specificity (138).
Two PDZs in two different adapter proteins—Na(+)/H(+) ex-
change regulatory cofactor NHERF3 and SH3 and multiple ankyrin 
repeat domains protein 1 SHANK1—have been previously identi-
fied to be able to bind TxF$ sequences (140), which makes both of 
them candidates for an interaction with the ACE2 C terminus. 
NHERF3 is colocalized with ACE2 in intestinal tissue, and its PDZ 
domains were previously validated to interact with PBMs in trans-
membrane proteins on the cytosolic side of the membrane (141), so it 
is possible that they come in proximity with the ACE2 tail containing 
the TxF$ motif and possibly bind it as a part of ion exchange regu-
lation of small-molecule transport activities. NHERF3 is known for 
its involvement in sodium ion–dependent transporter activity (142), 
and ACE2 was also shown to interact with a sodium-dependent trans-
porter (57), which could be one of the leads toward unraveling 
the possible interaction between NHERF3 and ACE2. Kliche et al. 
(48) confirmed ACE2 tail binding with good affinity for both 
NHERF3 and SHANK1. They also measured low micromolar affinity 
for the PDZ domain of SNX27, which is involved in retrograde trans-
port from the endosome to the plasma membrane. Although plausible, 
whether or not NHERF3 and SNX27 are PDZ domain–containing 
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proteins interacting with ACE2 is an open question that will require 
follow-up experiments in the cell.
Tyr781 in the ACE2 tail creates a potential multiway 
molecular switch regulated via phosphorylation
The tyrosine at residue 781 in ACE2 is a part of the motif patterns 
for four of the motifs listed above (Fig. 3 and Table 1) but must be 
phosphorylated to act as an SH2-binding motif. We searched the 
ACE2-related literature for reports of phosphorylation but were 
unable to find any with strong site identification. Examination of 
the human ACE2 entry in the database PhosphoSitePlus (143) re-
vealed that high-throughput (HTP) phosphoproteomic studies, but 
no low-throughput (LTP) studies, identify pTyr781. Thirteen HTP 
measurements identified phosphorylation at Tyr781, and this resi-
due is the only ACE2 phosphosite that is reproducible across multi-
ple HTP datasets (Fig. 4). For example, pTyr781 was one of 318 
unique phosphopeptides belonging to 215 proteins analyzed from 
an erlotinib-treated breast cancer cell line model (144). Therefore, 
this site fulfills the phosphorylation requirement to be an SH2- 
binding motif.
As outlined above, four candidate sequence motifs overlap in the 
region surrounding Tyr781: the YxxPhi endocytic sorting signal 
(ELM:TRG_ENDOCYTIC_2), an SH2 motif that mediates binding 
to SFKs, an NPY I-BAR–binding motif (ELM:LIG_IBAR_NPY_1), 
and the LIR autophagy motif (ELM:LIG_LIR_Gen_1). While the 
YxxPhi, NPY, and LIR motifs require an unphosphorylated state of 
Tyr781, the SH2 motif requires Tyr781 phosphorylation, creating the 
opportunity for a multiway phospho-switch acting in this region of 
ACE2 that directs different steps of the SARS-CoV-2 infection cy-
cle. In support of this proposal, Kliche et al. (48) confirmed that the 
ACE2-YxxPhi interaction is negatively regulated by phosphoryl-
ation and that binding to the FYN SH2 domain requires Tyr781 phos-
phorylation. The relative affinities of the ACE2 tail binders, which 
is still to be fully established, will dictate the competition between 
the interactions and the functional output. Current results indicate 
that the phosphorylated ACE2 tail can reach low micromolar affin-
ity for SFKs and that the unphosphorylated state can bind to the 
AP2 2 subunit with moderate affinity, while physiologically 
relevant interactions with autophagy components and I-BAR do-
mains are still to be demonstrated. The state of this switch could be 
controlled by protein localization and by tyrosine kinase activity 
involving SRC/Abl and other tyrosine kinases, which are known 
to have increased abundance during endosomal processes (115) 
and viral infection (18) including in coronaviruses (2, 25–27). 
Similar switches have been described before, as with the cytotoxic 
T lymphocyte–associated protein 4 (CTLA-4) receptors, where 
SRC tyrosine kinases dictate the binding preferences of overlapping 
YxxPhi and SH2-binding motifs. In the unphosphorylated state, en-
docytosis is favored, whereas T cell activation brings about Tyr 
phosphorylation, shutting down endosomal recycling and initiating 
signaling through the recruitment of SH2 domain–containing pro-
teins (106, 145–148). The CagA effector from Helicobacter pylori 
provides an example of a multiway molecular phospho-switch, 
where the choice for senescence versus cell proliferation is dictated 
by the SH2 domain–containing protein that forms a complex with 
phosphorylated CagA (24). Additional regulation can create a tem-
poral gradient of the phospho-signal: CagA leads to remodeling of the 
actin cytoskeleton through its sequential phosphorylation by tyro-
sine kinases. Initial phosphorylation by SRC creates a negative feed-
back loop that terminates SRC signaling through activation of the SRC 
inhibitor Csk in the early stages of infection, while phosphorylation 
by Abl kinases leads to concerted changes in the phosphorylation of 
actin-regulatory proteins that drive actin-cytoskeletal rearrange-
ments at later time points of infection (149).
Fig. 4. The summary for the ACE2 C-terminal tail provided by PhosphoSitePlus. No low-throughput (LTP) studies have been recorded in the database for ACE2. 
Thirteen high-throughput (HTP) studies have identified phosphorylation on Tyr781. Phosphosites reported in the extracellular part of ACE2 have only been reported once 
each and therefore are likely to be misidentified peptides.
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A similar temporal regulation could be at play in SARS-CoV-2 
endocytosis. This might be enacted by a Tyr781 phospho-switch. 
The early attachment phase could be characterized by unphospho-
rylated Tyr781 that allows the YxxPhi and NPY motifs to be active. 
During this phase, the YxxPhi motif could initiate RME by binding 
the AP2 complex 2 subunit, recruiting clathrin and other endocytic 
components to the viral attachment sites. In addition, some viruses 
can “surf” along filopodia by myosin-mediated actin cytoskeleton 
movements that transport the viral particles to the entry sites at the 
cell body, ultimately increasing their entry rate (125). The forma-
tion of these membrane protrusions could be promoted by the 
I-BAR–binding NPY motif. The relative affinity and availability of 
binders might dictate the sequential or concerted use of the YxxPhi 
and NPY motifs during the initial stage. Following the initial steps 
of membrane attachment and clathrin coat formation, actin po-
lymerization is required to internalize the endocytic vesicles. This 
second step could be brought about by SFK-mediated Tyr781 phos-
phorylation that leads to disengagement of the AP2 2 subunit and 
I-BAR–containing proteins and to activation of actin-regulatory 
proteins through SFK recruitment. SRC and Abl, two of the SFKs 
predicted to bind the SH2 motif, are known to promote RME and 
actin cytoskeletal rearrangements (113, 115).
An alternative scenario that is not mutually exclusive with tem-
poral regulation might be enabled by the multimeric nature of the 
spike protein and by attachment of several viral particles to a mem-
brane domain, leading to adjacent ACE2 tails on the intracellular 
side that expose both phosphorylated and unphosphorylated motifs, 
allowing these three signaling steps to take place simultaneously. 
The separation between the RBD-binding sites in the ACE2 dimer 
is 68 Å calculated from PDB:6m17 (57), in close agreement with the 
distance between RBDs in the up conformation (~66 Å) measured 
from PDB: 6x2b (61) (fig. S1). While the outward orientation of the 
RBD- binding sites in ACE2 might preclude stable contacts between two 
RBDs and an ACE2 dimer, the spatial proximity implies that both 
ACE2 subunits are likely activated by the dynamic interaction of a 
spike protein trimer with an ACE2 dimer. The presence of several 
parallel routes for the recruitment of cytoskeleton components in-
volving the NPY and SH2 motifs could provide the robustness 
needed to ensure the actin reorganization required for the uptake of 
virus-containing vesicles into the cytosol. Following endocytosis 
and fusion, viral components are released into the cell and viral rep-
lication takes place. SFKs have been shown to be inactive at the en-
dosomal compartments, which would lead to dephosphorylation of 
Tyr781 following endocytosis (115). During this phase, the last com-
ponent of the switch could come into play, when the ACE2 protein 
that remains bound to spike protein–coated membranes could pro-
mote the hijack of autophagy components necessary to assemble 
the viral replication factories. However, the functionality of the LIR 
motif has not yet been established and might require other PTMs of 
the ACE2 tail, as suggested by Kliche et al. (48).
Known and candidate motifs in the -integrin tails
Integrin  tails are short cytosolic C-terminal intrinsically disor-
dered regions, similar to the analyzed region of ACE2. The three 
most probable integrin  subunit candidates at play in SARS-CoV-2 
viral entry are 3, 6, and 1. The C-terminal tails of all three sub-
units share a high degree of sequence similarity (with 3 and 6 
being almost identical) and, similarly to ACE2, contain several 
known and candidate SLiMs (Table 1 and Fig. 5, A and B) that 
propagate signals in the cytoplasm and regulate integrin activity not 
only through intracellular pathways but also changing the structural 
state of the ectodomains determining ligand-binding capacity (150). 
In addition, all three integrin  tails are very highly conserved (figs. 
S4 to S6), hinting at their high functional importance.
Integrin  tails contain a highly charged patch in their membrane- 
proximal region (Fig. 5A). This region is indispensable for the inter-
action between integrins and tyrosine kinases, including the SRC 
kinase Fyn (151) and FAK, most probably via the direct interaction 
with paxillin (152). Through these interactions, integrins regulate 
cytoskeletal remodeling (153) and the promotion of cell survival 
(154), as well as regulation of FA assembly and cell protrusion for-
mation (155). In turn, FAK regulates integrin recycling and endoso-
mal trafficking (156, 157).
Now, there is no consensus sequence motif describing these in-
teractions, although a definition of HDR[KR]E has been proposed 
(158), matching integrins 1, 3, 5, and 6. This motif is under 
heavy regulation by several mechanisms. First, the interaction with 
tyrosine kinases seems to involve additional residues N-terminal of 
the charged motif core—most notably, the conserved lysine preced-
ing the hydrophobic patch (159)—that are only accessible in the 
active state of the integrin dimer, as these regions are buried in the 
membrane otherwise (160). Second, the D residue of the motif forms 
a salt bridge with the cytosolic tail of the  subunit of the integrin in 
the inactive conformation of the receptor. Thus, this motif region is 
dependent on integrin activation regulated by ligand binding and 
intracellular interactions mediated by the downstream NPxY motifs.
The tails of integrins 1, 3, and 6 contain two regions that 
match the apoPTB motif (Table 1 and Fig. 5A) as either NPxY (with 
two matches in integrin 1 and 1-1 matches in integrins 3 and 6) 
or φxNxxY (with 1-1 matches in integrins 3 and 6). Furthermore, 
these regions are known to have Tyr phosphorylation, matching the 
phosphorylated motif definition as well (ELM:LIG_PTB_Phospho_1). 
These regions are known to be able to form -turns and are recog-
nition sites for PTB domains. In addition, NPxY motifs are the ma-
jor sorting signals mediating interactions with FERM domains for 
regulating endosomal trafficking (161). In -integrin tails, these 
motifs recruit adaptor proteins and clathrin, serving as sorting sig-
nals (162), and the NPxY motifs in the 1 tail have a direct connec-
tion to viral entry for reovirus (163).
The NPxY motif switches mediate several interactions. The 
membrane-proximal NPxY motif binds talin-1, serving as a connec-
tion between the plasma membrane and the major cytoskeletal struc-
tures (164). Considering the expression profiles of talins, the most 
likely interaction partner of lung-expressed integrins is talin-1. Talin-1 
contains a FERM domain, similarly to Ezrin, which establishes a direct 
interaction with the SARS-CoV spike protein upon viral fusion (126). 
However, the interaction between the RBD and integrins offers the virus 
an earlier point of interference with the cytoskeletal system, being 
able to modulate it cooperatively with the ACE2 actin-regulatory 
elements (NPY and SH2 motifs) before and during cellular entry. The 
talin/integrin interaction, however, presents a feedback loop: The 
binding of talin on the cytoplasmic side induces a structural rear-
rangement on the ectodomains of integrins, enabling a higher affin-
ity interaction with RGD motif–containing ligands (165).
The membrane-proximal NPxY motif is also a binding site for 
docking protein 1 (DOK1), a negative regulator of integrin activation. 
DOK1 is in direct competition with talin for binding integrins (165). 
The competition is fundamentally influenced by phosphorylation 
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on Tyr783 (for integrin 1; fig. S7A), Tyr773 (for integrin 3; Fig. 5B), 
and Tyr762 (for integrin 6; fig. S7B) of the NPxY motif. The un-
phosphorylated motif has a higher affinity toward talin, whereas 
phosphorylation prefers DOK1 (166); thus, the tyrosine acts as a 
phospho-switch regulating integrin activation.
The membrane-proximal NPxY motif also presents a binding site 
for a largely phosphorylation-independent interaction with the in-
tegrin cytoplasmic domain–associated protein-1 (ICAP-1). ICAP-1 
is a fundamental regulator of the assembly of FAs and ICAP-1 
knockdown reduced FA assembly (167), possibly working in con-
junction with the membrane-proximal charged region. ICAP-1 
seems to be specific for 1, and hence, the therapeutic consider-
ations for targeting this pathway require the verification of the type 
of integrins expressed on AT2 cells (and other related cell types).
The membrane distal NPxY motif is a binding site for the FERM 
domain of kindlin (168). This interaction requires the integrin tail 
to be nonphosphorylated, and phosphorylation on Tyr795 (for inte-
grin 1) or Tyr785 (for integrin 3) can switch off the interaction 
with kindlin-2 (169) (no corresponding Tyr phosphorylation has 
been identified in 6 tails as of yet). Kindlin binding (together with 
talin binding) is a crucial step in integrin activation and hence reg-
ulates the availability of integrins for extracellular ligands (170) and 
was also suggested to play a role in TGF-1 signaling (171).
The two NPxY(-like) motifs in the integrin  tails not only con-
stitute two separate phospho-switches (Fig. 5, fig. S7, and Table 1) but 
also act in synergy to give rise to more complex regulation. Filamin 
and the PTB domain region of Shc1 each bind to both NPxY motifs 
(172, 173). Shc is an adaptor protein playing a key role in mitogen- 
activated protein kinase (MAPK) and Ras signaling pathways, and 
its interaction with integrin 3 requires both phosphorylations on 
Tyr773 and Tyr785 (172, 174). In contrast, binding of the immuno-
globulin domain of filamin-A requires both tyrosines to be in a non-
phosphorylated state. The filamin-A interaction can be considered 
as a main shutdown switch in integrin signaling, as this interaction 
induces the closed conformation of the integrin ectodomains, de-
creasing the chance of ligand binding (173). In addition, binding 
partners using both NPxY motifs may also serve as stronger modu-
lators of endosomal trafficking, switching on enhanced signals.
Integrins are known to be connected to autophagy regulation, 
and therefore, motif identification and analysis might help suggest 
possible underlying molecular mechanisms. The connection between 
autophagy and cell adhesion has already been described, showing 
that both reduced FAK signaling (175) and detachment from the 
extracellular matrix via integrins (176) enhance autophagy. Atg- 
deficient cells have enhanced migration properties, and at the mo-
lecular level, there seems to be a direct connection between Atg 
proteins and integrins as well: autophagy stimulation increases the 
colocalization of 1 integrin–containing vesicles with LC3-stained 
autophagic vacuoles, whereas autophagy inhibition decreases the 
degradation of internalized 1 integrins (177). In Drosophila cells, it 
has been shown that the Wiskott-Aldrich syndrome protein and 
SCAR homolog (WASH) plays a connecting role between integrin 
Fig. 5. Alignment of human integrins illustrating conserved motifs in the cytosolic C-terminal tail. (A) Multiple sequence alignment of human integrin C-terminal 
regions, not including the two most divergent  tails (4 and 8). The alignment shows motif conservation of the NPxY and LIR motifs (key residues displayed above). Red 
boxes mark the conservation range of the PTB motif in all sequences and the location of the LIR motif in integrin 3. Protein names, UniProt IDs, and sequence numberings 
are listed on the left side of the alignment. (B) Summary of the PTMs on the C-terminal tail of integrin 3. Details of the experimental evidence for the PTB tyrosine phos-
phorylations are highlighted: pTyr773 (pY773) and pTyr785 (pY785). Graph was obtained from PhosphoSitePlus.
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recycling and the efficiency of phagocytic and autophagic clearance 
(178). However, molecular details about how this connection is 
brought about are unclear.
Sequence analysis of integrin 3 and 6 tails shows a potential 
Atg-targeting LIR motif (Fig. 5A), similarly to the ACE2 tail. How-
ever, neither -integrin tails conform to the regular expression in-
troduced in earlier sections, as the hydrophobic residue following 
the core motif is a tyrosine (Tyr785 for 3 and Tyr774 for 6). Thus, to 
capture this instance as well, the regular expression needs to be 
modified to [EDST].{0,2}[WFY][^RKP][^PG][ILMV].{0,4}[LIVFMY]. 
LTP phosphorylation assays have determined that both Tyr773 and 
Tyr785 for 3 are phosphorylated in live cells (Fig.  5B). However, 
such assays have also determined additional phosphorylation sites 
in the 3 tail, Thr777, Ser778, Thr779, and Thr784. These phosphoryl-
ations are not connected to the NPxY motif switches in any known 
way but could serve as charge-based switches for the LIR motif. The 
peptide binding assays presented in the accompanying paper by 
Kliche et  al. (48) show that phosphorylations introduced in the 
N-terminal tandem sites yielded low micromolar binding affinities. 
In addition, phosphorylation of Tyr785 further increases affinity, 
showing that the loss of the favorable interaction mediated by the 
C-terminal hydrophobic residue can be well compensated for by 
electrostatic interactions. While the current motif definition does 
not exactly fit the 1 tail, there are also LTP phosphorylation assay 
data (179) for the existence of these phosphorylations in the corre-
sponding residues, hinting at the possibility of the presence of a 
slightly modified motif. For 3, as well as for 1 and 6 tails, the 
phosphorylation provides the negative charge required upstream of 
the FxxIxY LIR motif hydrophobic core. Phosphopeptides span-
ning the candidate region should also reveal whether the LIR motif- 
like region is a functional Atg-binding site in integrin 1. Such 
experiments can also shed light on the existence of a rheostat-like 
behavior of multi-phosphorylation, already demonstrated to a cer-
tain extent for the 3 LIR. The motif found in integrin 3 is also 
present in integrin 2, and the motif candidate identified in integrin 
1 is also present in integrin 6.
Potential synergy between the ACE2 and integrin 
intracellular motifs
Bringing together the candidate SLiMs identified in the integrin  
and ACE2 tails potentially strengthens the functional links between 
them and provides an emergent picture of SLiM-driven cooperative 
switches driving viral attachment, entry, and replication (Fig. 6). 
Following attachment of the spike protein to the receptors, the two 
NPxY motifs in the integrin subunit could act cooperatively with 
the apoPTB and YxxPhi motifs in ACE2 as sorting signals that me-
diate the internalization of viral particles into endosomes. The pres-
ence of several endocytic motifs in close proximity would strengthen 
the interaction with the endocytosis apparatus, creating a high- 
avidity environment for recruitment of RME components (107). 
During this time, the phosphorylated integrin NPxY motifs would 
also reinforce viral attachment through inside-out signaling, stabi-
lizing the integrin ectodomain in the open, high ligand affinity 
conformation. As discussed previously, RME also involves the recruit-
ment of adaptor molecules that activate rearrangements of the actin 
cytoskeleton required for the internalization of the endocytic vesi-
cle. At this stage, the NPY and SH2 motifs in ACE2 would recruit 
several molecules that mediate actin polymerization signaling, 
prominently I-BAR–containing proteins IRSp53 and IRTKS as well 
as actin cytoskeleton regulators activated by SFKs. While most of 
this actin signaling would serve to allow viral entry, additional actin 
recruitment processes could occur following viral fusion, such as 
that initiated by the interaction between the spike protein and 
Ezrin. Last, at later stages of infection, both integrins and ACE2 might 
remain attached to virus-associated DMVs and other replication- 
competent membranes where the RTC assembles. At this stage, 
ACE2 and integrins might cooperatively mediate the recruitment of 
autophagy components such as LC3 through the LIR motifs located 
in the cytosolic tails of both molecules.
SLiMs and their potential therapeutic implications
The analysis of candidate SLiMs in ACE2 and integrins suggests 
that SARS-CoV-2 hijacks both receptors, co-opting their SLiMs to 
drive viral attachment, entry, and replication. This creates an op-
portunity for drugging these interactions, or the processes they con-
trol, through host-directed therapies (HDTs) to prevent viral entry. 
On the basis of the identified candidate interactions, we collected a 
list of potentially useful drugs (Table 2) together with ChEMBL ac-
cessions (180); several are already registered for clinical trials (181).
The RGD sequence is used by a large number of viruses for cell 
attachment, via integrins (13). RGD mimics have been developed as 
inhibitors of integrin–extracellular matrix protein interaction for a 
variety of diseases. A cyclic RGD peptide [c-RGDf(NMe)V, cilen-
gitide] has been developed clinically for glioblastoma treatment and 
other cancers. It proved safe but did not enhance the survival bene-
fit (182). SARS-CoV-2 has a unique RGD sequence in the vicinity of 
the ACE2 binding region of its spike protein. It has been proposed 
that integrins may have a potential role for infectivity (12). If so, 
RGD mimetics might be able to block the RGD-binding site(s) on 
target cells and block the attachment of the virus. Another applica-
tion that has been suggested is bacterial sepsis (sepsis is also a 
dreaded complication in COVID-19 patients), and experimental 
evidence in animals is available (183). Cilengitide is relatively specific 
for integrin v3 but also active on v5, v1, v6, v8, IIb3, 41, 
and 51 (in decreasing order of activity). The antibody abituzumab 
(DI-17E6) is a pan-v antibody, meaning it is also active against 
other v integrins and, consequently, may be better suited for block-
ing virus entry. It has been clinically tested in several cancer indica-
tions (184, 185).
As discussed above, tyrosine kinase–mediated phosphorylation 
plays an important role in virus entry and maturation, and several 
tyrosine kinase inhibitors have entered the clinic and some show 
effects on viral infection in cell culture. For example, saracatinib, an 
SRC and Abl inhibitor that has completed several clinical trials, 
mainly targeting cancers, inhibited replication of different corona-
viruses including MERS-CoV, SARS-CoV, and HCoV-229E in cell 
culture infection experiments (27). After internalization and endo-
somal trafficking, imatinib, an Abl inhibitor, prevented fusion of 
SARS-CoV and MERS-CoV virions at the endosomal membrane in 
infected cell culture experiments (25). Using the avian model virus 
IBV, imatinib and two other Abl inhibitors (GNF2 and GNF5) pre-
vented the fusion of the spike protein to the membrane of the target 
cell as well as cell-cell fusion and syncytia formation (2). More re-
cently, tyrphostin A9, a platelet-derived growth factor receptor 
(PDGFR) tyrosine kinase inhibitor, came out from an HTP screen-
ing using cytopathic effect as readout and also showed in vitro in-
hibitory capacity to transmissible gastroenteritis virus (TGEV), an 
alphacoronavirus that infects pigs (26). The authors also showed 
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that tyrphostin A9 has a broad antiviral spectrum, being active 
against three other tested coronaviruses: MHV in murine L929 cells, 
porcine epidemic diarrhea virus in primate Vero cells, and feline 
infectious peritonitis virus in feline CCL-94 cells. The mode of ac-
tion was found to be through p38 MAPK, at the post-adsorption 
stage. As FAK has been implicated in viral entry for other viruses 
including influenza A (186), experimental drugs targeting FAK, in-
cluding some in clinical trials (187), can be considered for studying 
potential spike protein–induced integrin signaling. Now, 39 tyro-
sine kinase inhibitors are approved by the U.S. Food and Drug Ad-
ministration (FDA): 11 target nonreceptor protein–tyrosine kinases 
and 28 inhibit receptor protein–tyrosine kinases (188). Consequent-
ly, tyrosine kinase inhibitors may be good candidates to test for 
their effect on SARS-CoV-2. For example, an inhibitor of the Abl 
and PDGFR kinases, flumatinib mesylate, showed 42% reduction of 
SARS-CoV-2 infection of Vero E6 cells at 
2.5 M (189). As part of the United King-
dom’s ACCORD (Accelerating COVID-19 
Research & Development) program, a clin-
ical trial is underway to evaluate bem-
centinib, a specific inhibitor of the receptor 
tyrosine kinase AXL in COVID-19 (190). 
AXL acts as a pleiotropic inhibitor of 
innate immunity (191) and is also a re-
ceptor for Ebola virus (192).
A number of protease inhibitors are 
now discussed for SARS-CoV-2 treat-
ment. Serine protease inhibitor camo-
stat mesylate is active against TMPRSS2 
and blocks cell entry (4). Nafamostat 
mesylate—originally developed as a 
tryptase inhibitor (193)—also has been 
shown to inhibit TMPRSS2. Nafamo-
stat mesylate is an approved anticoag-
ulant in Japan, with clinical testing for 
COVID-19 infections now being con-
ducted. The spike protein of SARS-CoV-2 
contains a furin cleavage sequence 
(PRRARS|V). Consequently, furin con-
vertase inhibitors are considered as an-
tiviral agents (194). A prime example of 
such inhibitors is decanoyl-RVKR-CMK, 
which has been shown to inhibit cleav-
age of the SARS-CoV-2 spike protein at 
the S1/S2 site by furin (90). A large drug 
screen identified four drugs that targeted 
host cysteine proteases in SARS-CoV- 2–
infected human cells including VBY-
825 (cathepsin B/L), ZLVG CHN2, ONO 
5334 (cathepsin K), and MDL-28170 
(cathepsin B and calpain I/II), with the 
latter two inhibiting SARS-CoV-2 rep-
lication in human induced pluripotent 
stem cell (iPSC) pneumocytes (189).
Many viruses enter the cell via endo-
cytosis, and a number of candidate SLiMs 
relevant for SARS-CoV-2 infection are 
related to endocytosis (see above). Chlor-
promazine, an antipsychotic dopamine 
D2 antagonist developed in the 1950s, is a potent endocytosis inhibitor 
(which likely explains its reputation as a “dirty drug” and some of its 
marked side effects, which can include low white blood cell levels). 
Like other tricyclic antipsychotics, the drug specifically inhibits the 
dynamin motor protein that is required to close off the endocytic vesicle 
at the plasma membrane (195). Anecdotally, it is thought that chlor-
promazine (and presumably other tricyclic antipsychotics) might be 
protecting patients in psychiatric hospitals, and a clinical trial is now 
planned for COVID-19 (196). The potential use of endocytosis inhibi-
tors such as amiodarone (197) and chlorpromazine in coronavirus infec-
tion is further discussed elsewhere (198). Another drug candidate, 
apilimod, acts later in the endosomal pathway by inhibiting the phospho- 
inositol kinase PIKfyve and blocks the SARS-CoV-2 entry pathway 
(38). Apilimod has been shown to strongly inhibit SARS-CoV-2 
infection in two additional studies with the half-maximal inhibitory 
Fig. 6. Model of the proposed interplay between motifs in the interface between SARS-CoV-2 and a human 
host cell to achieve RME. Receptors of the SARS-CoV-2 (gray) and a human host cell (light blue) motifs involved in 
viral recognition and entry are shown in colored boxes. Elements shown in one of the monomers of a homotrimer 
(spike) or homodimer (ACE2) are also present in the other proteins forming that complex. Lines below motif boxes 
represent each of the overlapping motifs in that specific region. Arrows indicate the related cellular process, and the 
protein known to interact with their respective motif is indicated in parenthesis. Phosphorylation sites are shown as 
inverted triangles, with the respective sequence position indicated. For the -integrin tail, the PTB/apoPTB phospho- 
switch is depicted as two separate versions of the same motif region, and the subscripts represent the motif order in 
the sequence. SLiMs mediating interactions are represented with boxes of different colors, protease cleavage sites 
with hexagons (PCs, furin-like proprotein convertases; T, TMPRSS2), phosphorylation sites with inverted triangles, and 
structural motifs with ovals. The color code is as follows: cleavage sites, yellow hexagon; apoPTB/PTB motif, orange; 
endocytic sorting signal motif, purple; I-BAR–binding motif, dark red; LIR motif, blue; MIDAS motif, gray; SH2 motif, 
green; PBM motif, magenta; RGD motif, bright red; and CendR motif, brown. † indicates that these motifs had been 
previously experimentally validated.
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concentration (IC50; 0.007 m) in human lung cells (199) and 
the half-maximal response (EC50; 0.023 m) in Vero E6 cells (189). 
Tyrphostin AG 538 (originally described as an inhibitor of insulin- 
like growth factor 1 receptor) is a preclinical inhibitor of the phospho- 
inositol kinase PI5P4K (gene name PIP4K2A) (199) and showed 
55% reduction of SARS-CoV-2 infection in Vero E6 cells (189). 
PIKfyve generates PtdIns5P, a regulatory phospholipid found on 
intracellular membrane systems including endosomes (201), whereas 
PI5P4K removes PtdIns5P by converting it to PtdIns(4, 5)P2. Thus, 
apilimod and tyrphostin AG 538 might be targeting aspects of the 
same regulatory system controlling endosomal fates.
The threonine-specific AP2-associated protein kinase 1 (AAK1) 
phosphorylates the 2 subunit of the AP2 complex, promoting 
clathrin-mediated endocytosis (107). The related cyclin G–associated 
kinase (GAK) is also a regulator of endocytosis (202). It has been 
suggested that baricitinib, which is an AAK1 and GAK inhibitor in 
Table 2. Drugs acting on various processes involved in viral entry and infection.  
Name of drug Mode of action Clinical status COVID19 ClinicalTrials.gov IDs* Other details ChEMBL ID
†
Inhibitors of viral attachment






Shown to be relevant in 
pancreatic fibrosis 590799
Nafamostat mesylate TMPRSS2 inhibition Approved (Japan) NCT04473053
Also inhibits human 
tryptase.‡ Has strong 
anticoagulant effect
3989553
Decanoyl-RVKR-CMK Furin inhibition Preclinical –
Has been shown to 
inhibit CoV-2 spike 
cleavage at S1/S2 site 
by furin.§ Because the 
NRP1 receptor binds 
after cleavage, furin 
inhibition is potentially 
more relevant
3126388
Abituzumab Integrin inhibition (v6, pan-v)
Phase 2 in oncology – May also be relevant in fibrosis 2109621
Cilengitide Integrin inhibition (v3, v5, v6)
Phase 3 in oncology – May also be relevant in fibrosis, sepsis 429876
Suramin
Entry/early replication 
inhibitor, mode of 
action unknown
FDA approved –






Amiodarone Inhibits late endosomes FDA approved NCT04351763
Cell culture–based 








FDA approved NCT04354805, NCT04366739
Antipsychotic drug 
routinely used as 




Inhibits PIKfyve, a 




infection. Good safety 
profile from (failed) 















Inhibits cathepsin L 
(late endosomes and 
lysosome)
FDA approved – Glycopeptide antibiotic 2367892
continued on the next page
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addition to being a Janus kinase (JAK) inhibitor, be tested in 
COVID-19 (203).
The situation with targeting autophagy seems unclear. Autophagy 
activators might help the cell to consume incoming virus or speed 
up the establishment of the viral replication complexes and accelerate 
disease. Autophagy inhibitors might work in later stages of infec-
tion to dampen viral production, but this will depend on whether 
autophagy is active at the time or if the constituent components 
have been captured and effectively shut down. Several inhibitors/
activators have been reported (a selection is listed in Table 2), which 
can target autophagy and multiple auxiliary signals feeding into the 
process of autophagy (204–207). One such axis is via the mTORC1 
Name of drug Mode of action Clinical status COVID19 ClinicalTrials.gov IDs* Other details ChEMBL ID
†













Also inhibits JAK kinase 2105759
BI-853520 FAK inhibitor Phase 1 –
FAK has been 
implicated in the 
Influenza A virus cell 
entry and replication¶
3544961
Saracatinib Src and Abl inhibitor Phase 2 in oncology – Now also considered for Alzheimer’s disease 217092
Tyrphostin A9
PDGF receptor kinase 
inhibitor (plus other 
activities)





modulation (plus other 
activities?)
FDA approved NCT04510194 Approved for type 2 diabetes 1431
Rapamycin
Everolimus mTORC1 inhibition FDA approved NCT04482712





















moderate effect; VAL 
targets MERS-CoV in 
cell culture,# known to 
inhibit SKP2
1448
NVP-BEZ235/dactolisib Autophagy induction Phase 2 – PI3k/Akt/mTOR 1879463
Spautin-1
Autophagy down-
regulation by inhibition 
of USP10 and USP13
Preclinical –
Inhibits dengue virus 
replication in tissue 
culture model.** 







accumulation in the 
endosomes
FDA approved NCT04377308
Used in treatment of 
major depressive 
disorder and obsessive 
compulsive disorder. 
Inhibits SARS-CoV-2 
replication in Calu-3 
and Vero E6 cells‡‡
41
*Clinical trial information can be checked by clicking the IDs (181).   †Drug details are accessible by clicking ChEMBL IDs (180).   ‡Reference 
(193).   §Reference (90).   ║Reference (197).   ¶Reference (186).   #Reference (207).   **Reference (205).   ††Reference (204).   ‡‡Reference (206).
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(mammalian target of rapamycin complex 1)  complex. Active mTORC1 
keeps the autophagy process inhibited by phosphorylating the ULK 
(Unc-51–like autophagy activating kinase) complex that is a key regula-
tor in autophagy. Inhibition of mTORC1 activates autophagy. Multiple 
FDA-approved mTOR inhibitors are known and include rapamycin 
and everolimus. Rapamycin has been shown to be effective in cell 
culture for countering MERS-CoV infection (208) but has so far shown 
negative results in SARS-CoV-2 infection assays using Vero E6 cells 
(209), although the stage of infection might be crucial for the desired 
outcome. Simvastatin is another drug that is known to increase auto-
phagy via the mTOR pathway (210). Simvastatin has also been 
reported to alleviate airway inflammation in a mouse asthma model 
(211). Another autophagy modulator is niclosamide that regulates 
autophagy by targeting the autophagy regulator Beclin1 via the SKP2 
E3 ligase. In MERS-CoV infection, reduced Beclin1 levels lead to 
blocking fusion of autophagosomes and lysosomes and hence the 
virus protects itself in the host (43). Inhibiting SKP2 by niclosamide 
relieves Beclin1, allowing autophagosome-lysosome fusion and re-
sumption of autophagy to reduce the MERS-CoV production. In 
addition, niclosamide (an FDA-approved drug for tapeworm infes-
tations) and valinomycin (a naturally occurring antibiotic) have 
been shown to target SARS-CoV in cell cultures as well (207).
DISCUSSION
Examination of viral and cellular proteins that are known (or likely) 
to be involved in SARS-CoV-2 cell entry has proved a fruitful exer-
cise in identifying multiple candidate SLiMs that might partake in 
the process. Because of the low sequence information content of 
SLiMs, it is difficult to get strong statistical support, and therefore, 
amino acid conservation over long evolutionary time periods is one 
of the most critical observations in this work. Experimental follow- 
up is essential before a SLiM can be considered to be functional. A 
first experimental step to indicate that these motifs might be func-
tional is to test in vitro their ability to bind partner protein domains 
with an expected low micromolar or high nanomolar affinity, as is 
typical for SLiM interactions. In the case of PTB/apoPTB motif 
variants, it is difficult to do this quickly as the binding domain fam-
ilies are large and have not been systematically analyzed for motif 
preference, despite the known importance of this domain family in 
endocytosis and vesicle trafficking (136). However, in the accompa-
nying experimental paper, Kliche et al. (48) were able to test peptide- 
domain binding for most of the newly predicted motifs in the ACE2 
and integrin tails. Of those that could be quickly tested, several bound 
with plausible affinities, some were ambiguous, and some did not 
bind under the conditions of the experiments. Therefore, the ACE2 
PBM, the SFK SH2-binding motif, the AP 2-binding motif, as well 
as the integrin 3 phospho-LIR, are now available for their potential 
roles to be studied in cellular endocytic-autophagosome pathways 
both under normal conditions and when under pathogenic abuse.
Our observations of SLiM candidates in the viral entry system reveal 
previously unknown possible interactions mediating viral infection and 
reflect additional areas of the cell where drug repurposing for HDT 
might be explored. However, understanding the SARS-CoV-2 entry 
system has become more complicated and also more confusing. ACE2 
is considered the canonical receptor for both SARS-CoV and SARS-
CoV-2. Yet, the very rare expression of ACE2 in lungs implies that 
it cannot be the receptor underlying the severe lung pathology. In-
tegrins are available to play this role and, as we have discussed, are 
promising but not yet conclusively proven receptors. NRP1 has also 
been shown to be a SARS-CoV-2 receptor (91) and could also play 
a role in the lung disease. Like ACE2 and  integrins, we note that 
this newly identified receptor has a conserved apoPTB motif candi-
date and also a C-terminal SEA$ motif that binds the PDZ domain 
of GIPC1 (212), an endocytosis adapter protein (fig. S8A). GIPC1 
can also bind an SDA$ motif in integrin 5 (213). Integrins and 
NRP1 are involved in co-regulated signaling (text S1) and could 
therefore work together as SARS-CoV-2 receptors. The possibility 
of additional receptors should not be excluded. Earlier work with 
SARS-CoV has shown that several plasma membrane lectins can act 
as co-receptors (32), and in SARS-CoV-2, lectins expressed by innate 
immune cells bind the spike protein with high affinity and can pro-
mote viral entry (214). The cytosolic tails of a number of the lectin 
receptors are substrates of tyrosine kinases. Although tyrosine kinase 
inhibitors have frequently been shown to dampen pathogen invasion 
and disease progression in cell culture, there has been little effort to 
move these findings into the clinic (24). Because of their widespread 
use in cancer, the safety profiles of tyrosine kinase inhibitors are well 
known and we wonder whether this might be a neglected opportunity. 
COVID-19 might now drive the medical research forward: For exam-
ple, in a small-scale trial, acalabrutinib, an inhibitor of BTK (Bruton’s 
tyrosine kinase) that is an activator of macrophages, appears to be 
effective in dampening excessive inflammation in the lung of 
COVID-19 patients (215) and a larger trial is underway (190).
Drugging the cell to cure the pathogen using HDTs is unlikely to 
fully remove a virus. This would also be undesirable, because the 
immune system must mount a defense to prevent viral reinfection. 
Rather, dampening viral load during viral invasion or replication 
should be the target to give the host defenses time to respond. It is 
well known that drugs like Tamiflu, which slows influenza exit and 
therefore entry into uninfected cells, can only have a strong effect 
when taken prophylactically or early in infection (216). Depending 
on the importance of integrins in SARS-CoV-2 lung cell entry, given 
that it has become clear that ACE2 is barely expressed in the lung, 
altering virus-cell interactions is a possible role for cilengitide or 
other molecules that hamper integrin binding. An endocytosis in-
hibitor might play a similar role and is independent of receptor type. 
However, for any such inhibitor that passes the blood-brain barrier, 
effects on mood and other brain operations are an inevitable side 
effect: Even so, the endocytosis inhibitor chlorpromazine is a widely 
used drug with a well-known safety profile (217). AAK1 inhibition 
is also known to affect endocytosis, but there are no specific inhibi-
tors in human trials, leading to the suggestion that the less specific 
JAK inhibitor baricitinib be tested (203).
Because of the presence of the cell attachment motif RGD in 
SARS-CoV-2, integrin inhibitors seem worthwhile to explore further. 
Cilengitide [a cyclic peptide that proved safe in patients but failed to 
show a survival benefit in glioblastoma (182)] is a relatively selective 
integrin v3 and v5 inhibitor, with low activity on various other 
integrins. It might be useful in two phases: It could block virus at-
tachment to target cells, and it has also been proposed as a potential 
treatment in sepsis by preventing the attachment of bacteria to en-
dothelial cells that can be RGD dependent (183). Sepsis was the 
most frequently observed complication among COVID-19 patients 
in Wuhan (218). Another potential application of integrin inhibi-
tors, especially integrin v6, would be lung fibrosis—patients on 
respirators tend to develop lung fibrosis and show increased v6 
levels (219). The antibody abituzumab (DI-17E6) is a pan-v antibody 
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with high potency on v6, i.e., also active against several v integ-
rins, and may consequently be better suited for blocking virus entry 
or may be suitable for lung fibrosis. It has been clinically tested in 
several cancer indications (184, 185), and proved safe, but did not 
achieve a survival benefit. Very recently, the integrin v6 inhibitor 
GSK3008348 has been shown to have an effect on lung fibrosis in a 
mouse therapeutic model (220).
The first large-scale proteomics study expressed 26 tagged SARS- 
CoV-2 proteins individually in human embryonic kidney (HEK) 
293T cells, using affinity purification mass spectrometry to create a viral- 
human protein-protein interaction map and identified FDA-approved 
drugs, which were screened as inhibitors of these interactions (209). 
However, because this screen was not performed in the context of 
viral infection, it might have failed to reveal interactions essential 
for viral entry. The drug assays revealed positive results for inhibi-
tors of mRNA translation and modulators of Sigma1/2 receptors and 
returned negative results for serine protease inhibitors (camostat and 
nafamostat), ACE inhibitors (captopril and lisinopril), mTOR in-
hibitors (rapamycin and sapanisertib), and a limited subset of tyro-
sine kinase inhibitors (midostaurin, ruxolitinib, and pazopanib). 
Translation and splicing regulators were further found as positive 
hits in another large-scale proteomics and translatome study (221). 
Another large drug screen using A549 lung cells identified AXL and 
AKT kinase inhibitors gilteritinib and ipatasertib and metallopro-
teinase inhibitors prinomastat and marimastat as promising drug 
candidates (222). A phosphoproteomic screen revealed that CK2, 
p38/MAPK, and cell cycle kinase pathways were regulated by SARS-
CoV-2 infection, identifying kinase inhibitors that worked to inhibit 
viral replication. However, because tyrosine kinases were not strong-
ly represented in the studied dataset (199), future work should help 
establish the role played by the tyrosine kinase signaling pathway in 
SARS-CoV-2 infection. While the positive hits in the latter studies 
provided useful targets for follow-up, the fact that the drug testing 
was performed in Vero E6 cells implies that negative results should 
be taken with caution until infection assays reflecting more physio-
logical conditions are tested. A more recent large-scale drug screen-
ing found positive results for two tyrosine kinase inhibitors and 
confirmed strong inhibitory potency in lung iPSCs for two cysteine 
protease inhibitors and apilimod, with the latter also working in lung 
explant models (189). The three strongest inhibitors in this study 
affected viral entry, with apilimod showing potency comparable to 
that of remdesivir. This suggests that combination therapies using 
remdesivir together with apilimod or other kinase inhibitors de-
pending on the infection stage might provide promising avenues 
for fighting COVID-19 infection.
In summary, we have presented evidence at the sequence level 
for SLiMs in ACE2 and  integrins with the potential to function in 
viral attachment, entry, and replication for SARS-CoV-2. We have 
identified several candidate molecular links and testable hypotheses 
that might help uncover the (still poorly understood) mechanisms 
of SARS-CoV-2 entry and replication. Because most of these motifs 
belong to host proteins acting as viral receptors, they are not revealed 
by virus-centered proteomic interaction assays. That they may well 
be functional, however, is indicated by sequence conservation, in 
some cases for hundreds of millions of years. In addition, the motifs 
are in appropriate cellular contexts to interact with their partner 
proteins. These putative motifs originally lacked direct experimen-
tal evidence, but the accompanying paper from Kliche et al. (48) 
shows that ACE2 YxxPhi, SH2, and PBM motifs and the integrin 3 
phospho-LIR bind to partner domains in vitro. Further experimen-
tal follow-up will yield insights into RME for the SARS-CoV-2 vi-
rus and, in addition, for the role of ACE2 in the normal cell, where 
it surely has much more functionality than its role as an ACE. Over-
all, the collection of candidate motifs in this system suggests that 
a range of HDTs might be explored including RGD inhibition, tyro-




Sequences of the spike protein, ACE2, and  integrins, together with 
homologous sequences, were retrieved from UniProt (222) (release 
6 May 2020). The RatG spike protein sequence (Fig. 1) was retrieved 
from GenBank (224), and sequences of hagfish (Eptatretus burgeri) 
proteins were retrieved from UniParc (UniProt archive). All num-
berings defining regions in these proteins refer to the canonical 
sequences. RGD motif and its flanking region (2 amino acids) con-
servation were checked by using full-length high-quality spike pro-
tein sequences retrieved from the GISAID (53, 54) on 9 June 2020.
Identification of SLiMs
Candidate and known functional motifs were identified in the ana-
lyzed sequences using the ELM web server (23). The tail of ACE2 
was also examined for SH2 predictions with ModPepInt server (116). 
Structural and context filters were used with their default settings. 
Motif candidates were manually inspected and were correlated with 
information from sequence conservation, available structures, and 
known phosphorylation sites, if applicable.
Protein alignments, structures, and abundance
Protein sequences were aligned using Clustal omega (225) using 
sequences extracted from UniProt and UniParc as inputs. Align-
ments were visualized using Jalview (226) and Clustal colors. The 
neighbor-joining tree in Fig. 1B was generated by Jalview with de-
fault parameters, and only the sequence regions shown in Fig. 1A 
were used. Protein structures were retrieved from the PDB (227) 
and were visualized using UCSF Chimera (228). Expression levels for 
various human proteins were taken from the Human Protein Atlas (81).
PTM sites
PTM sites in ACE2 and integrin 1, 3, and 6 tails were taken from 
PhosphoSitePlus (v6.5.9.3) (143). Visualization of PTM data was 
done using the images generated by the PhosphoSitePlus web server 
using both HTP and LTP phosphorylation data.
SUPPLEMENTARY MATERIALS
stke.sciencemag.org/cgi/content/full/14/665/eabd0334/DC1
Text S1. Extended discussion on the potential of NRPs in SARS-CoV-2 cell entry.
Fig. S1. The structural feasibility of simultaneous integrin and ACE2 binding by SARS-CoV-2 
spike protein trimers.
Fig. S2. Structural indication of a functional spike protein RBD:integrin v6 interaction.
Fig. S3. Alignment of human ACE2 transmembrane helix and C-terminal intracellular tail with 
homologous sequences of representative vertebrate collectrins from UniProt reference proteomes.
Fig. S4. Alignment of homologous sequences of integrin 3 transmembrane helices and 
intracellular tails.
Fig. S5. Alignment of homologous sequences of integrin 1 transmembrane helices and 
intracellular tails.
Fig. S6. Alignment of homologous sequences of integrin 6 transmembrane helices and 
intracellular tails.
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Fig. S7. PTMs in -integrin tails.
Fig. S8. Transmembrane and intracellular regions of NRP1 and NRP2.
Table S1. SH2 domain specificity for the candidate ACE2 tail SH2 motif.
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ways to prevent viral infection.
Together, these findings have identified a potential link between autophagy and integrin signaling and could lead to new 
machinery but also found that these interactions were regulated by the phosphorylation of SLiM-adjacent amino acids.
many of these predicted SLiMs interacted with target peptides in various components of the endocytosis and autophagy 
 not only confirmed thatet al.may engage the endocytic and autophagic machinery. Using affinity binding assays, Kliche 
thatshort amino acid sequences, called short linear motifs (SLiMs), in the cytoplasmic tails of ACE2 and various integrins 
 predicted the presence ofet al.receptor ACE2 and potentially others, including integrins. Using bioinformatics, Mészáros 
SARS-CoV-2, the virus that causes COVID-19, enters cells through endocytosis upon binding to the cell surface
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